Clinical Pilot Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- The number of serious and non-serious adverse events occurring during the trial
Study Overview
Brief Summary
Clinical pilot study to assess safety and performance of Neola®, a novel lung monitoring device for neonates
Detailed Description
The purpose of the study is to demonstrate that the device is safe and performs as intended under anticipated use conditions.
The performance of Neola will be evaluated in terms of ability to continuously measure and display the relative lung volume and absolute oxygen gas concentration on neonates. The results of this clinical investigation will provide further information for the design of a subsequent full-scale clinical investigation.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 1 Day to 14 Days (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Preterm or term born neonates with gestational age between 28 and 40 weeks
- •Post-natal age between 1 and 14 days
- •Weight between 1000 g and 3000 g
- •Signed informed consent prior to any study related procedures by the legal representatives of the patient
- •Legal representatives are 18 years or older
- •Legal representatives can absorb and understand the content of the informed consent form
Exclusion Criteria
- •Known cardiopulmonary congenital anomalies
- •Patients with trisomies or other chromosomal abnormality
- •Patients not expected to survive
- •Non-intact skin or other skin conditions (such as skin lesions) that do not allow the use of skin adhesives. (e.g., Bullous impetigo, Staphylococcal scalded skin syndrome, localized lesions of herpes simplex virus)
- •Thorax curvature does not allow placement of the probe sets without air between the surface of the probes and the skin.
Arms & Interventions
Arm 1
Intervention: Monitoring (Device)
Outcomes
Primary Outcomes
The number of serious and non-serious adverse events occurring during the trial
Time Frame: 2 days
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of serious and non-serious adverse events occurring during the trial.
The number of device related events including skin reactions
Time Frame: 2 days
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of device related events including skin reactions.
Secondary Outcomes
- The device's ability to continuously measure and present the clinical parameters while the neonates are in a resting state/sleeping(2 hours)
- The device's ability to continuously measure and present the clinical parameters during normal handling of the neonates(2 hours)
- The adhesive performance of the probes in terms of ability to be repositioned and stay attached(2 hours)